CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Mismatch Repair Deficiency Testing for Colorectal Cancer Patients

Last updated: September 2, 2015
Project Number: OP0522
Product Line: Optimal Use
Result type: Report

CADTH has completed a project to inform decision-makers about the appropriate use of testing for DNA mismatch repair deficiency (dMMR). The health technology assessment addresses policy issues including the appropriate populations for dMMR testing for identifying new families with a hereditary predisposition to certain cancers (Lynch syndrome) and for predicting the response to chemotherapy. These issues are addressed by evaluating the diagnostic accuracy, clinical utility, and cost-effectiveness of dMMR testing in a universal testing scenario, as well as within specific subpopulations (for example, based on age or family history). Patient preferences and experiences and the ethical implications of dMMR testing are also addressed.

The project has four key components:

  • Protocol
  • Science report
  • Ethics report
  • Recommendations